Place Title Here
Resident NameMentor Name
Thoughts• Remember for your project proposal, you will probably not
have results and discussion. However, you can let them know where you are at in the process and ask for their guidance and input. This is your opportunity to educate the faculty and your fellow residents as to how you plan to accomplish the project. Plus, you are drawing on the experience of others who have already been there and done that. By involving others early in the process, you will be able to manage the project. If not, the project will manage you.
• If all else fails, ask for help!
More Thoughts• As in life, there is a process/steps that we go through. Birth,
childhood, teenager, adult, elder, death (you get the idea). Currently, in this process, you are an OBGYN resident who has the opportunity to do research. Though research maybe relatively new to you, it has been present since the beginning of time. Therefore cherish the fact that those before you have already constructed a pathway for you to follow. It is call the scientific method. These steps follow:
Stating the questions Literature search
ObjectiveDesign Materials and MethodResults DiscussionConclusion
After you give your project proposal, you should be through the first, five steps. In other words, your are over halfway to completion.
Rule of Thumb
• Don’t put any information on a slide that will not fit reasonably on a 3 X 5 index card.
Introduction(or Background)• Heading
– Included sub-headingsIncluded sub-headings11
1) Author, Year (references)
Cyr61 Structure
• 379 amino acids• 42 kDa• Cysteine rich • Encoded on chromosome 1
Example
CCN1 0 AAAAIGFBPIGFBP VWCVWC TSP1TSP1 CTCT
IGFBP: Insulin-like growth factor binding protein motifVWC: von Willibrand Type C moduleTSP1: thrombospondin type I repeatCT: C--terminal module
Objectives
• To…
Materials and Methods• Design
– Retrospective, Prospective, Cohort, Observational, Double blind, randomized trial, survey
• Patient Demographics – Age– Ethnicity– G’s and P’s.
• Methods– Describe methods (use project protocol template)– Inclusion/exclusion criteria– Statistical Analysis (Power Analysis)
Study Design
PT POSTED FOR ABDOMINAL OR VAGINAL HYSTERECTOMY
NOT ELIGIBLE ELIGIBLE
CEFAZOLIN + PLACEBO CEFAZOLIN + METRONIDAZOLE
Cultures, Surgery Cultures, Surgery
Postoperative Follow-up Postoperative Follow-up
Example
Results
Example
• Western blot analysis of ECC1 for Cyr61
– Treated with diethylstilbestrol (DES)
– Treated with epidermal growth factor (EGF)
Regulation in Endometrium
ResultsEndometrial Adenocarcinoma
Normal endometrium
Mid
-sec
reto
ryPr
olife
rativ
e
Endometrial adenocarcinoma
Cyr61 Immunostaining• Expression increased in endometrial cancer compared with normal mid-secretory endometrium
Example
Results
Example
Endometrial Adenocarcinoma• RT-PCR for Cyr61
in normal cycling endometrium and in endometrial adenocarcinoma
(* P<0.001)
ResultsTable 1. Preoperative BV Status versus Postoperative Infection Rate versus Metronidazole/Placebo
Group BV Status Postop Infection
No Postop Infection P
MetronidazolePositive
IntermediateNegative
3 (17.6%)3 (27.3%)3 (12.5%)
14 (82.4%) 8 (72.7%)21 (87.5%)
0.6
Placebo Positive
IntermediateNegative
2 (16.7%)2 (11.1%)6 (25.0%)
10 (83.3%)16 (88.9%)18 (75.0%)
0.5
Example
Discussion
• Start discussion here
Conclusions
• Start conclusions here
Future Studies
• Start future studies here
Acknowledgments
• Add acknowledgments here